GSK (GSK) 20-F2014 FY Annual report (foreign)

Filed: 27 Feb 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accomplish, accrual, aggregate, allergy, alli, andAbreva, andBoost, andBoostrix, andFenbid, andForm, andHycamtin, andMekinist, andMepron, andPanadol, andPromacta, andSoriatane, andVentolin, andZinacef, April, arriving, attrition, Augmentin, Bactroban, Benlysta, Boostrix, bothXyzal, bound, BRAF, bribe, bribing, build, butAquafresh, byAbreva, bySeretide, Changsha, Chinese, clearance, clearer, cold, collaboration, commercialisation, committed, competing, Constellation, contrary, customary, deed, Dermatology, digit, discontinued, dose, dry, dyslipidemia, Ebola, eleven, Ellipta, exit, expertise, feel, fine, flu, Fluarix, FluLaval, fromTafinlar, fromVotrient, GSKCI, guilty, Hampton, Hepsera, highlighted, Hunan, IIa, IIb, improper, Indian, influenza, inSensodyne, Insufficient, Intermediate, Leo, life, likelihood, mainlyCombivir, marking, maximum, mechanism, melanoma, merit, metastatic, metered, Middle, milestone, Ministry, mission, modified, monotherapy, ofBreo, ofContac, official, ofLovaza, ofProlia, ofRelenza, ofVotrient, omitted, oncology, outbreak, outsourced, pandemic, Philip, Planet, powder, precise, preferred, primary, productsTafinlar, project, Province, Quadrivalent, rapidly, Rare, reassessment, recipient, regionTykerb, revaluation, reward, RMB, Rohner, Rotarix, SAPA, season, Serevent, shelving, smaller, solution, split, Stiefel, stockbuilding, strict, stronger, subsequent, subsequently, suspension, Synflorix, tail, theLucozade, thrombocytopenia, trending, unilaterally, unlawful, unwinding, upfront, uptake, Urs, verdict, Vesicare, voluntary, week, withAdvair, withSensodyne, workforce, Zeffix

Removed: Robert, Wilson

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GSK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 15.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (Nos. 333-194744, 333-194744-01 and 333-194744-02) of GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc., and in the Registration Statements on Form S-8 (Nos. 333-88966, 333-100388 and 333-162702) of GlaxoSmithKline plc of our report dated 27 February 2015, relating to the financial statements and the effectiveness of internal control over financial reporting of GlaxoSmithKline plc, which appears in this Annual Report on Form 20-F.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

London, England

27 February 2015